The RE-LY study demonstrated the safety and efficacy of dabigatran relative to warfarin for
stroke prevention in non-valvular atrial fibrillation. It is important to further evaluate safety …

BACKGROUND: Dabigatran is a recently introduced direct thrombin inhibitor licensed for
use as an oral anticoagulant for stroke prevention in non-valvular atrial fibrillation. Our …

Dabigatran etexilate (Pradaxa®) is approved in the EU for the prevention of stroke and
systemic embolism in patients with nonvalvular atrial fibrillation (NVAF) and one or more risk …

Background Novel oral anticoagulants are available for the management of atrial fibrillation
and are considered more convenient to use than warfarin. Objective The main objective of …

Aims Randomized trials showed non-inferior or superior results of the non-vitamin-K-
antagonist oral anticoagulants (NOACs) compared with warfarin. The aim of this study was …

Objective: This analysis was performed to evaluate the efficacy in stroke prevention and
safety of dabigatran in Chinese nonvalvular atrial fibrillation (NVAF) patients enrolled in RE …

Objectives: The aim of this study was to assess the efficacy and safety in an “everyday
clinical practice” population of anticoagulant-naïve patients with atrial fibrillation (AF) treated …

Objectives: The goal of this study was to analyze the impact of dabigatran plasma
concentrations, patient demographics, and aspirin (ASA) use on frequencies of ischemic …

This study aimed to evaluate the variability of dabigatran plasma concentration and the
association with clinical events in Chinese patients treated with dabigatran etexilate (DE) for …

Unlike other international regulatory agencies, the US FDA did not approve the dabigatran
110 mg dose for the prevention of stroke and systemic embolism in patients with non …